These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 18500360)

  • 1. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
    Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy.
    Klitgaard H; Matagne A; Gobert J; Wülfert E
    Eur J Pharmacol; 1998 Jul; 353(2-3):191-206. PubMed ID: 9726649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.
    Matagne A; Margineanu DG; Potschka H; Löscher W; Michel P; Kenda B; Klitgaard H
    Eur J Pharmacol; 2009 Jul; 614(1-3):30-7. PubMed ID: 19383493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models.
    Leclercq K; Matagne A; Provins L; Klitgaard H; Kaminski RM
    J Pharmacol Exp Ther; 2020 Jan; 372(1):11-20. PubMed ID: 31619464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?
    Klitgaard H
    Epilepsia; 2001; 42 Suppl 4():13-8. PubMed ID: 11564119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man.
    Matagne A; Klitgaard H
    Epilepsy Res; 1998 Jun; 31(1):59-71. PubMed ID: 9696301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats.
    Christensen KV; Leffers H; Watson WP; Sánchez C; Kallunki P; Egebjerg J
    BMC Neurosci; 2010 Jan; 11():9. PubMed ID: 20105316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brivaracetam augments short-term depression and slows vesicle recycling.
    Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
    Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brivaracetam: a rational drug discovery success story.
    Rogawski MA
    Br J Pharmacol; 2008 Aug; 154(8):1555-7. PubMed ID: 18552880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats.
    Löscher W; Hönack D
    Eur J Pharmacol; 1993 Mar; 232(2-3):147-58. PubMed ID: 8467854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus.
    Tai KK; Truong DD
    J Neural Transm (Vienna); 2007; 114(12):1547-51. PubMed ID: 17690949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of Approved Drugs with Synaptic Vesicle Protein 2A.
    Danish A; Namasivayam V; Schiedel AC; Müller CE
    Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28220535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats.
    Kitano Y; Komiyama C; Makino M; Kasai Y; Takasuna K; Kinoshita M; Yamazaki O; Takazawa A; Yamauchi T; Sakurada S
    Epilepsia; 2005 Oct; 46(10):1561-8. PubMed ID: 16190926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-epileptogenic effects of synaptic vesicle protein 2A modulation in a mouse model of Alzheimer's disease.
    Silva JC; Shen Y; Chan J; Kwan P; Jones NC
    Epilepsy Res; 2022 Oct; 186():106994. PubMed ID: 35973309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.
    Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M
    Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.